You are here
Survey: New Therapies Will Drive Growth in Parkinson’s Disease Drug Market Over Next Decade
According to a new report issued by Decision Resources Group, a health care research firm located in Burlington, Mass., the Parkinson’s disease (PD) pharmacotherapy market will grow 5% annually from $2.3 billion in 2013 to $3.8 billion in 2023. This growth will be fueled by the launch of several emerging therapies — including new molecular entities in established drug classes, reformulations of time-tested products, and novel first-in-class entrants that target a range of clinically important subpopulations facing diverse unmet needs.
Interviewed experts showed enthusiasm for CVT-301(Civitas) –– a self-administered, adjunctive, as needed, inhaled L-dopa therapy –– as an effective, patient-friendly alternative to injectable formulations of apomorphine for PD patients experiencing “off” episodes. The report predicts that CVT-301 will earn approximately $700 million in the U.S. market in 2023, with the potential for additional revenues through a global launch.
In addition, according to the report, Nuplazid (pimavanserin, Acadia Pharmaceuticals) –– a small-molecule, selective serotonin inverse agonist –– is poised to become the first therapy approved specifically to treat PD-associated psychosis, a key comorbidity that is undertreated and underserved by current off-label options, which can exacerbate motor symptoms. Following a projected U.S. and European launch beginning in 2016, the report forecasts that Nuplazid will increase the number of patients receiving an antipsychotic for PD-associated psychosis and will garner PD sales of approximately $400 million in 2023.
Although levodopa remains the patient share leader in PD, the pharmacokinetic shortcomings of marketed levodopa products left interviewed experts open to additional reformulations. However, based on available data, it remains unclear whether emerging brands, such as Rytary (carbidopa/levodopa, Impax Laboratories), will deliver a clinically meaningful advance for patients needing levodopa, which has been generically available for many years, the report says.
“Opportunity still remains for adjunctive therapies to address the motor response complications associated with chronic levodopa treatment,” said analyst Tamara Blutstein, PhD. “Nevertheless, competition from clinical mainstays will make it difficult for late entrants like Newron/Zambon/Meiji Seika Pharma’s monoamine oxidase B inhibitor safinamide, Bial/Ono’s catechol-O-methyltransferase inhibitor opicapone, and Adamas’ extended-release amantadine formulation Nurelin to garner a substantial share of the market unless significant clinical differentiation can be shown.”
She added: “Near-term opportunity also exists for therapies that target other motor symptoms that are not adequately controlled with current treatments, including gait dysfunction, freezing, and postural imbalance — but the real future of PD treatment lies in disease-modifying therapies, a number of which are currently in early-stage development. Evolving insights into the etiology and pathology of PD will help identify additional targets for disease-modifying therapies, which will remain an important focus of therapeutic development in PD over the long term.”
Source: Decision Resources Group